Clinical Trials Sponsored by Adamas Pharmaceuticals, Inc.

Total 4968 results

Adamas Pharmaceuticals, Inc.

Terminated

Efficacy and Safety of Amantadine Hydrogen Chloride (HCl) ER Tablets in Parkinson's Disease Subjects With LID (ALLAY-LID-II)

Parkinson's Disease | Levodopa Induced Dyskinesia (LID)

France, Germany, Canada, United States, Spain
Adamas Pharmaceuticals, Inc.

Terminated

Efficacy and Safety of Amantadine Hydrochloride (HCl) ER Tablets to Treat Parkinson's Disease Patients With LID. (ALLAY-LID-I)

Parkinson's Disease | Levodopa Induced Dyskinesias (LID)

France, Spain, Germany, Canada, United States
Adamas Pharmaceuticals, Inc.

Completed

Open-Label Safety Study of ADS-5102 in PD Patients With LID

Parkinson's Disease (PD) | Dyskinesia | Levodopa Induced Dyskinesia (LID)

France, Spain, United States, Canada, Germany, Austria
Adamas Pharmaceuticals, Inc.

Completed

ADS-5102 for the Treatment of Levodopa Induced Dyskinesia (EASE LID Study) (EASE LID)

Parkinson's Disease | Dyskinesia | Levodopa Induced Dyskinesia (LID)

United States, Canada
Adamas Pharmaceuticals, Inc.

Completed

Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment

Multiple Sclerosis | Walking Impairment

United States
Adamas Pharmaceuticals, Inc.

Completed

A Safety and Efficacy Study of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment

Multiple Sclerosis | Walking Impairment

United States, Canada
Adamas Pharmaceuticals, Inc.

Completed

Safety and Efficacy of ADS-5102 in Multiple Sclerosis Patients With Walking Impairment

Multiple Sclerosis | Walking Impairment

United States, Canada
Adamas Pharmaceuticals, Inc.

Completed

Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia (EASE LID 3)

Parkinson's Disease (PD) | Dyskinesia | Levodopa-Induced Dyskinesia (LID)

France, Spain, United States, Germany, Austria
Adamas Pharmaceuticals, Inc.

Completed

Oral Triple Combination Antiviral Drug Therapy for Treatment of Influenza A in Immunocompromised Subjects (PO206)

Influenza

United States, Australia, Canada, Netherlands, Singapore
Adamas Pharmaceuticals, Inc.

Completed

Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study) (EASED)

Parkinson's Disease | Dyskinesia | Levodopa Induced Dyskinesia

United States
Adamis Pharmaceuticals Corporation

Terminated

Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients.

Covid19

United States
Adamis Pharmaceuticals Corporation

Withdrawn

Beclomethasone Dipropionate HFA in Adult and Adolescent Subjects With Mild to Moderate Persistent Asthma

Asthma
Adamis Pharmaceuticals Corporation

Withdrawn

Beclomethasone Dipropionate HFA in Adult and Adolescent Subjects With Persistent Asthma

Asthma
Adamis Pharmaceuticals Corporation

Unknown

Dose-Escalation and Safety Study of APC-100 for the Treatment of Prostate Cancer

Prostate Cancer

United States
Oregon Health and Science University
Adamas Pharmaceuticals, Inc.

Recruiting

Effect of GOCOVRI (Amantadine, Extended Release Capsules) on Gait in Parkinson's Disease

Parkinson Disease

United States
Aramis Biosciences, Inc.

Completed

A Study to Evaluate the Safety, Tolerability, and Efficacy of A197 in Subjects With Dry Eye Disease

Dry Eye Disease

United States
AlaMab Therapeutics (Shanghai) Inc.

Recruiting

Study to Evaluate the Safety and Pharmacokinetics of ALMB-0166 in Patients With Acute Spinal Cord Injury

Acute Spinal Cord Injury

China
AlaMab Therapeutics (Shanghai) Inc.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

A Study to Evaluate the Safety and Efficacy of ALMB-0168 in Patients With Osteosarcoma

Osteosarcoma
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

A Study of EDP-514 in Patients With Chronic Hepatitis B Virus Infection Who Are Not Currently on Treatment

Chronic HBV Infection

Hong Kong, Taiwan
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

Drug-Drug Interaction Study Between EDP-938, Itraconazole, Rifampin, and Quinidine in Healthy Subjects

RSV Infection

United States
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

A Study of EDP-514 in Healthy Subjects (Part 1) and Patients With Chronic Hepatitis B Virus Infection (Part 2)

Chronic HBV Infection

United States, Canada
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

A Study of EDP-938 in Healthy Subjects

RSV Infection

United States
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

A Study of EDP 305 in Healthy Subjects and Subjects With Presumptive NAFLD

Presumptive NAFLD

United States
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

Drug-Drug Interaction Study Between EDP-938, Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy Subjects

RSV Infection

United States
Alexza Pharmaceuticals, Inc.
Pharmaceutical Research Associates

Unknown

Observational Study Evaluating the Safety of ADASUVE® in Agitation Associated With Schizophrenia or Bipolar I Disorder

Agitation,Psychomotor

United States
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

Drug-Drug Interaction Study Between EDP-938, Cyclosporine and Prednisone in Healthy Adult Subjects

RSV Infection

United States
ADMA Biologics, Inc.

Completed

Study to Evaluate Safety and Pharmacokinetics of BIVIGAM® in Primary Immune Deficiency Subjects Aged 2 to 16

Humoral Immune Response

United States
ADMA Biologics, Inc.

Active, not recruiting

A Study About Low Blood Pressure in Patients With Primary Immunodeficiency Disease Treated With Immune Globulin Products

Primary Immune Deficiency Disorder

United States
ADMA Biologics, Inc.

Completed

Open Label, Phase III Study of NABI-IGIV 10% [Immune Globulin Intravenous(Human), 10%] In Subjects With Primary Immune Deficiency Disorders (PIDD)

Primary Immune Deficiency Disorders (PIDD)

United States
ADMA Biologics, Inc.

Completed

Pharmacokinetics, Efficacy, and Safety Study of RI-002 (IGIV) in Subjects With Primary Immunodeficiency Diseases (PIDD)

Primary Immune Deficiency Disorder

United States
ADMA Biologics, Inc.

Completed

RI-001 in Immunosuppressed Respiratory Syncytial Virus (RSV) Infected Patients at Risk of Lower Tract RSV Illness

Lower Respiratory Tract Infection | Upper Respiratory Tract Infection

United States, Canada
ADMA Biologics, Inc.

Recruiting

An Open Label, Multicenter Study to Evaluate the Pharmacokinetics, Efficacy and Safety of ASCENIV™ (IGIV) in Pediatric Subjects With Primary Immunodeficiency Diseases (PIDD)

Primary Immune Deficiency

United States
ADMA Biologics, Inc.

Terminated

Randomized Phase II Study of Hepatitis C Immune Globulin Intravenous (Human), Civacir(TM), in Liver Transplantation

Transplantation Infection | Evidence of Liver Transplantation | Sequelae of Viral Hepatitis

United States
Jazz Pharmaceuticals
Otsuka Pharmaceutical Development & Commercialization, Inc.

Completed

Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer (SPRAY III)

Pain | Advanced Cancer

United States, Germany, United Kingdom, Mexico, Poland, Romania, Bulgaria, Czechia, Hungary, Puerto Rico
RVL Pharmaceuticals, Inc.
Osmotica Pharmaceutical US LLC

Completed

A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MS (OS440-3004)

Multiple Sclerosis | Spasticity, Muscle

Serbia, Belarus, Bosnia and Herzegovina, Bulgaria, Croatia, Moldova, Republic of, Poland
RVL Pharmaceuticals, Inc.
Osmotica Pharmaceutical US LLC

Completed

Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis

Multiple Sclerosis | Spasticity

United States, Russian Federation, Ukraine
Tetraphase Pharmaceuticals, Inc.

Completed

Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Complicated Intra-abdominal Infections (IGNITE1)

Complicated Intra-abdominal Infections

United States, France, Ukraine, Argentina, Bulgaria, Romania, South Africa, Germany, Estonia, Russian Federation, Lithuania, Czechia, Latvia
Tetraphase Pharmaceuticals, Inc.

Completed

Study to Compare TP-434 and Ertapenem in Community-acquired Complicated Intra-abdominal Infections

Complicated Intra-abdominal Infection

United States, Latvia, Lithuania, Romania, India, Bulgaria
Tetraphase Pharmaceuticals, Inc.

Completed

Efficacy and Safety Study of Eravacycline Compared With Meropenem in Complicated Intra-abdominal Infections (IGNITE4)

Complicated Appendicitis | Complicated Intra-abdominal Infections

Ukraine, United States, Bulgaria, Romania, Estonia, Russian Federation, Lithuania, Hungary, Latvia, Georgia, Czechia
Tetraphase Pharmaceuticals, Inc.

Completed

A Thorough QT/QTc Study to Evaluate the Effects of an Intravenous Infusion of Eravacycline (TP-434) on Cardiac Repolarization

Normal Healthy Subjects
High Point University
Adidas International, Inc.

Completed

Changes in Footwear Comfort and Performance in High School Football Players

Foot | Footwear

United States
RVL Pharmaceuticals, Inc.
Osmotica Pharmaceutical US LLC

Completed

One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity

Multiple Sclerosis | Spasticity

United States, Russian Federation, Ukraine
Tetraphase Pharmaceuticals, Inc.

Completed

A Phase 1, Open-Label Study to Assess the Single-Dose Pharmacokinetics of Eravacycline in Subjects With Impaired Hepatic Function and Healthy Subjects

Impaired Hepatic Function

United States
Tetraphase Pharmaceuticals, Inc.

Completed

A Phase 1, Open-Label Study to Assess the Single-Dose Pharmacokinetics of Eravacycline in Subjects With End Stage Renal Disease and Healthy Subjects

End Stage Renal Disease
Jazz Pharmaceuticals
Otsuka Pharmaceutical Development & Commercialization, Inc.

Completed

Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer

Pain | Advanced Cancer

United States, United Kingdom, Bulgaria, Belgium, Poland, Hungary, Romania, Czechia, Puerto Rico, Lithuania, Germany, Latvia
Jazz Pharmaceuticals
Otsuka Pharmaceutical Development & Commercialization, Inc.

Completed

A Two-Part Study of Sativex® Oromucosal Spray for Relieving Uncontrolled Persistent Pain in Patients With Advanced Cancer

Pain | Advanced Cancer

Israel, Italy, Taiwan, United Kingdom, Bulgaria, Hungary, India, Australia, Lithuania, Poland, Spain, Romania, Germany
Jazz Pharmaceuticals
Otsuka Pharmaceutical Development & Commercialization, Inc.

Completed

Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain

Pain | Advanced Cancer

Italy, United States, Taiwan, United Kingdom, Czechia, Bulgaria, Belgium, Latvia, Mexico, Lithuania, Poland, Romania, Hungary, Spain, Israel, Germany, Puerto Rico, Australia
RVL Pharmaceuticals, Inc.
Osmotica Pharmaceutical US LLC

Completed

A Study to Evaluate the Long-term Safety of Arbaclofen Extended-Release Tablets for Patients With Spasticity Due to MS (OS440-3005)

Multiple Sclerosis | Spasticity, Muscle

United States
RVL Pharmaceuticals, Inc.
Osmotica Pharmaceutical US LLC

Withdrawn

To Assess Effects of Arbaclofen ER Tablets Compared With Placebo on Sperm Parameters in Male Subjects With MS

Multiple Sclerosis | Sperm

United States
Tetraphase Pharmaceuticals, Inc.

Completed

Efficacy and Safety Study of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections

cUTI

United States, Latvia, Poland, Czechia, Romania, Ukraine, Russian Federation, Georgia, Colombia, Bulgaria, Estonia, Greece, Hungary, Israel, Italy, Mexico, Moldova, Republic of, South Africa

Clinical Trials Sponsored by Adamas Pharmaceuticals, Inc.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kyrgyzstan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations